What's Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])

  • ID: 4497210
  • Report
  • Region: Global
  • 203 Pages
  • Kalorama Information
1 of 4
This Report Provides Analysis of the Current Global Market, Looking at the Market by Structure, by Target, and by Indication

FEATURED COMPANIES

  • AbbVie
  • Biogen Inc.
  • Eleven Biotherapeutics
  • InterveXion Therapeutics
  • Neurimmune
  • Sanofi
  • MORE

Monoclonal antibodies (mAbs) - large protein molecules produced by white blood cells (WBCs) that seek out and destroy harmful foreign substances - are finding wide application in many areas of medicine and biologic science. These antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory. Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances. They have very useful in quantitating types of WBCs and subgroups of lymphocytes. They are also used in the diagnosis of leukemia. More recently, monoclonal antibodies have been used in the treatment of malignancies. They have been used to treat transplant rejection episodes, purge bone marrow of tumor cells in bone marrow transplants, and remove mature T cells that cause GVH disease in bone marrow transplants. There are several types of monoclonal antibodies on the market and in development.

What's Trending in Monoclonal Antibodies provides analysis of the current global market, looking at the market by structure, by target, and by indication, including the following data points:

  • Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 (Chimeric, Humanized, Human, Others)
  • Leading Products: Chimeric Structure mAb Market, 2017-2022
  • Leading Products: Humanized Structure mAb Market, 2017-2022
  • Leading Products: Human Structure mAb Market, 2017-2022
  • Monoclonal Antibody Market by Target, 2017 and Forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)
  • Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)

In terms of indication, the monoclonal antibody market is largely derived from treatments in the autoimmune and oncology segments, with other segments representing a smaller share of the market at the current time. By 2022, there is expected to be some shift in sales distribution to other segments.

The report goes beyond broad indication category to provide detail on the following segments:

  • Rheumatoid Arthritis mAb Market, 2017-2022
  • Crohn's Disease/Ulcerative Colitis mAb Market, 2017-2022
  • Psoriasis mAb Market, 2017-2022
  • Other Autoimmune Disease mAb Market, 2017-2022
  • Cancer Treatment mAb Market by Type, 2017-2022 (Breast Cancer, Colon Cancer, Lymphoma, Leukemia, Myeloma, Melanoma)
  • Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales
  • Multiple Sclerosis mAb Market, 2017-2022
  • Asthma mAb Market, 2017-2022
  • Macular Degeneration mAb Market, 2017-2022

What's Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) also looks at the market in terms of regional markets and the competitive situation. Developments in regional markets are a major driver for the monoclonal antibody market. The report provides an overview of these markets, going beyond the U.S. market to discuss the Europe market and rest of world market, which largely includes the Asia Pacific markets including Japan. Further, the report provides a competitor summary. It is no surprise that the early developers of monoclonal antibodies continue to be the leaders in the segment today. Some two decades ago, Abbott (with MedImmune), Johnson & Johnson (with Centocor) and Roche (with Genentech) launched three of today's leading mAb therapies.

Data provided include:

  • Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 (United States, Europe, Rest of World, Global Market)
  • Monoclonal Antibody Competitor Market Share, 2017

Company profiles of the major participants in the monoclonal antibody market are provided, including:

  • AbbVie
  • Ablynx
  • Agensys
  • Alder Biopharmaceuticals
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aptevo Therapeutics
  • AstraZeneca/MedImmune
  • Bayer
  • Biocon Ltd
  • Biogen Inc.
  • BioInvent International
  • Biotest AG
  • Boehringer Ingelheim GmbH
  • CBT Pharmaceuticals
  • Celgene
  • Celldex Therapeutics
  • Celltrion, Inc.
  • Coherus BioSciences, Inc
  • CytoDyn
  • Eisai
  • Eleven Biotherapeutics
  • Eli Lilly & Co.
  • FibroGen Inc.
  • Five Prime Therapeutics
  • Fujifilm Kyowa Kirin Biologics
  • Genmab A/S
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Humanigen, Inc. (previously KaloBios Pharmaceuticals)
  • Immune Pharmaceuticals
  • ImmunoGen Inc.
  • Immunomedics Inc.
  • Innate Pharma
  • InterveXion Therapeutics
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co, Ltd
  • MacroGenics
  • Mapp Biopharmaceutical
  • Merck & Company
  • Merrimack Pharmaceuticals
  • Momenta Pharmaceuticals Inc.
  • MorphoSys
  • Morphotek
  • Mylan N.V.
  • Nascent Biotech
  • Neurimmune
  • Nordic Nanovector
  • Novartis/Sandoz
  • Novimmune SA
  • OncoMed Pharmaceuticals
  • OncoQuest
  • Oncternal Therapeutics
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis Co Ltd
  • Sanofi
  • Seattle Genetics
  • Shire PLC
  • Sorrento Therapeutics
  • TaiMed Biologics
  • Takeda Oncology
  • TESARO
  • TEVA Pharmaceutical Industries Ltd
  • TG Therapeutics
  • ThromboGenics
  • UCB S.A.
  • Unum Therapeutics
  • Vitaeris
  • XBiotech
  • Xencor
  • XOMA
  • Y-mAbs Therapeutics

Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals. A combination of primary and secondary research was used to determine market size for monoclonal antibodies by structure, target and indication. In instances where multiple indications are listed for one product the most common or used indication is listed. Billing databases and pricing charts were used as supplementary sources of information while interviews with key company representatives were conducted to verify initial findings. Primary research methods included telephone interviews and email correspondence with company representatives, researchers, government representatives, and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of formulating forecast models and for confirming early findings related to market potential.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Biogen Inc.
  • Eleven Biotherapeutics
  • InterveXion Therapeutics
  • Neurimmune
  • Sanofi
  • MORE

1. Executive Summary

  • Overview
    • Table Monoclonal Antibody Market Development, 1986-2022
  • Scope and Methodology
  • Market Summary
    • Table Monoclonal Antibody Market, 2017-2022 ($ millions)

2. Introduction

  • The Development of Monoclonal Antibodies
  •  Table Monoclonal Antibody Approvals by Year, FDA and EMA, 1990 through December 2017
  • Naming Monoclonal Antibodies
    • Table Monoclonal Antibody Source Identifiers
    • Table Monoclonal Antibody Disease or Target Class Identifiers
    • Table Examples of Monoclonal Antibodies by Name Origin
  • New Monoclonal Antibody Nomenclature Rules
    • Table USAN Requirements for Monoclonal Antibodies
  • DEVELOPMENT Outlook
    •  Table Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017
    •  Table Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017
    •  Table Monoclonal Antibody Development Pipeline, Distribution of Projects by Therapeutic Class, 2017
    •  Table Monoclonal Antibody Development Pipeline, Distribution of Projects by Phase, 2017

3. Monoclonal Antibody Markets by Structure

  • Table Monoclonal Antibodies by Structure - Mouse, Chimeric, Humanized, Human
  • Market Overview
    • Table Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market Distribution by Structure, 2017 (%)
    • Table Monoclonal Antibody Market Distribution by Structure, 2022 (%)
  • Chimeric
    • Table Leading Products: Chimeric Structure mAb Market, 2017-2022 ($ millions)
  • Humanized
    • Table Leading Products: Humanized Structure mAb Market, 2017-2022 ($ millions)
  • Human
    • Table Leading Products: Human Structure mAb Market, 2017-2022 ($ millions)

4. Monoclonal Antibody Markets by Target

  • Market Overview
    • Table Monoclonal Antibodies by Target - TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6 Examples
    • Table Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market Distribution by Target, 2017 (%)
    • Table Monoclonal Antibody Market Distribution by Target, 2022 (%)

5. Monoclonal Antibody Markets by Indication

  • Market Overview
    • Table Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions)
    • Table Monoclonal Antibody Market Distribution by Indication, 2017 (%)
    • Table Monoclonal Antibody Market Distribution by Indication, 2022 (%)
  • Autoimmune Diseases
    • Table Rheumatoid Arthritis mAb Market, 2017-2022 ($ millions)
    • Table Crohn's Disease/Ulcerative Colitis mAb Market, 2017-2022 ($ millions)
    • Table Psoriasis mAb Market, 2017-2022 ($ millions)
    • Table Other Autoimmune Disease mAb Market, 2017-2022 ($ millions)
  • Oncology Indications
    • Table Cancer Treatment mAb Market by Type, 2017-2022 ($ millions)
    • Table Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)
    • Table Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)
  • Neurological Indications
    • Table Multiple Sclerosis mAb Market, 2017-2022 ($ millions)
  • Respiratory Treatments
    • Table Asthma mAb Market, 2017-2022 ($ millions)
  • Other Areas of Treatment
    •  Table Macular Degeneration mAb Market, 2017-2022 ($ millions)

6. Market Summary

  • Market Influences
  • Global Demographics
    • Table Global Population, through 2050 (population in millions)
    • Table Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  •  Chronic Diseases
    • Table Mortality: Chronic vs. Acute, 2015
  • Cost Containment
    • Table The Cost of Monoclonal Antibodies
  • Reimbursement Landscape: A Deciding Factor for Success
  • The Biosimilar Movement
  • Regional Market Overview
    •  Table Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 ($ millions)
    •  Table Monoclonal Antibody Market Summary by Geographic Region, 2017 ($ millions)
  • Leading Products
    •  Table Leading Monoclonal Antibodies based on 2017 Sales ($ millions)
  • Market Breakdown of Monoclonal Antibodies
    •  Table Monoclonal Antibody Market by Structure, 2017 and 2022 ($ millions)
    •  Table Monoclonal Antibody Market by Target, 2017 and 2022 ($ millions)
    •  Table Monoclonal Antibody Market by Indication, 2017 and 2022 ($ millions)
  • Competitor Summary
  • Genentech/Roche
  • AbbVie
  • Janssen Biotech/J&J
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Amgen
  • Alexion
  • Biogen
  • Eli Lilly & Co.
    • Table Monoclonal Antibody Competitor Market Share, 2017 ($ millions)

7. Company Profiles

  • AbbVie
    •  Table AbbVie Corporate Summary
  • Ablynx
    •  Table Ablynx Corporate Summary
  • Agensys
    •  Table Agensys (with Astellas) Corporate Summary
  • Alder Biopharmaceuticals
    •  Table Alder Biopharmaceuticals Corporate Summary
  • Alexion Pharmaceuticals
    •  Table Alexion Pharmaceuticals Corporate Summary
  • Allergan
    •  Table Allergan Corporate Summary
  • Amgen
    •  Table Amgen Corporate Summary
  • Aptevo Therapeutics
    •  Table Aptevo Corporate Summary
  • AstraZeneca/MedImmune
    •  Table AstraZeneca/MedImmune Corporate Summary
  • Bayer
    •  Table Bayer Corporate Summary
  • Biocon Ltd
    •  Table Biocon Corporate Summary
  • Biogen Inc.
    •  Table Biogen Corporate Summary
  • BioInvent International
  •  Table BioInvent Corporate Summary
  • Biotest AG
    • Table Biotest AG Corporate Summary
  • Boehringer Ingelheim GmbH
    • Table Boehringer Ingelheim Corporate Summary
  • CBT Pharmaceuticals
    • Table CBT Corporate Summary
  • Celgene
    •  Table Celgene Corporate Summary
  • Celldex Therapeutics
    • Table Celldex Therapeutics Corporate Summary
  • Celltrion, Inc.
    •  Table Celltrion Corporate Summary
  • Coherus BioSciences, Inc
    • Table Coherus Biosciences Corporate Summary
  • CytoDyn
    • Table CytoDyn Corporate Summary
  • Eisai
    • Table Eisai Corporate Summary
  • Eleven Biotherapeutics
    • Table Eleven Biotherapeutics Corporate Summary
  • Eli Lilly & Co.
    • Table Eli Lilly & Co. Corporate Summary
  • FibroGen Inc.
    • Table FibroGen Inc. Corporate Summary
  • Five Prime Therapeutics
    • Table Five Prime Therapeutics Corporate Summary
  • Fujifilm Kyowa Kirin Biologics
    • Table Fujifilm Kyowa Kirin Biologics Corporate Summary
  • Genmab A/S
    • Table Genmab A/S Corporate Summary
  • Gilead Sciences
    • Table Gilead Sciences Corporate Summary
  • GlaxoSmithKline plc
    • Table GlaxoSmithKline Corporate Summary
  • Humanigen, Inc. (previously KaloBios Pharmaceuticals)
    • Table Humanigen Inc. Corporate Summary
  • Immune Pharmaceuticals
    • Table Immune Pharmaceuticals Corporate Summary
  • ImmunoGen Inc.
    • Table ImmunoGen Inc. Corporate Summary
  • Immunomedics Inc.
    • Table Immunomedics Inc. Corporate Summary
  • Innate Pharma
    • Table Innate Pharma Corporate Summary
  • InterveXion Therapeutics
    • Table InterveXion Therapeutics Corporate Summary
  • Johnson & Johnson
    • Table Johnson & Johnson Corporate Summary
  • Kyowa Hakko Kirin Co, Ltd
    • Table Kyowa Hakko Kirin Corporate Summary
  • MacroGenics
    • Table MacroGenics Corporate Summary
  • Mapp Biopharmaceutical
    • Table Mapp Corporate Summary
  • Merck & Company
    • Table Merck Corporate Summary
  • Merrimack Pharmaceuticals
    • Table Merrimack Corporate Summary
  • Momenta Pharmaceuticals Inc.
    • Table Momenta Pharmaceuticals Corporate Summary
  • MorphoSys
    • Table MorphoSys Corporate Summary
  • Morphotek
    • Table Morphotek Corporate Summary
  • Mylan N.V.
    • Table Mylan Corporate Summary
  • Nascent Biotech
    • Table Nascent Biotech Corporate Summary
  • Neurimmune
    • Table Neurimmune Corporate Summary
  • Nordic Nanovector
    • Table Nordic Nanovector Corporate Summary
  • Novartis/Sandoz
    • Table Novartis/Sandoz Corporate Summary
  • Novimmune SA
    • Table Novimmune SA Corporate Summary
  • OncoMed Pharmaceuticals
    • Table OncoMed Pharmaceuticals Corporate Summary
  • OncoQuest
    • Table OncoQuest Corporate Summary
  • Oncternal Therapeutics
    • Table Oncternal Therapeutics Corporate Summary
  • Pfizer, Inc.
    • Table Pfizer Corporate Summary
  • Regeneron Pharmaceuticals
    • Table Regeneron Corporate Summary
  • Roche
    • Table Roche Corporate Summary
  • Samsung Bioepis Co Ltd
    • Table Samsung Bioepis Corporate Summary
  • Sanofi
    • Table Sanofi Corporate Summary
  • Seattle Genetics
    • Table Seattle Genetics Corporate Summary
  • Shire PLC
    • Table Shire PLC Corporate Summary
  • Sorrento Therapeutics
    • Table Sorrento Therapeutics Corporate Summary
  • TaiMed Biologics
    • Table TaiMed Biologics Corporate Summary
  • Takeda Oncology
    • Table Takeda Oncology Corporate Summary
  • TESARO
    • Table TESARO Corporate Summary
  • TEVA Pharmaceutical Industries Ltd
    • Table Teva Corporate Summary Corporate Summary
  • TG Therapeutics
    • Table TG Therapeutics Corporate Summary
  • ThromboGenics
    • Table ThromboGenics Corporate Summary
  • UCB S.A.
    • Table UCB S.A. Corporate Summary
  • Unum Therapeutics
    • Table Unum Therapeutics Corporate Summary
  • Vitaeris
    • Table Vitaeris Corporate Summary
  • XBiotech
    • Table XBiotech Corporate Summary
  • Xencor
    • Table Xencor Corporate Summary
  • XOMA
    • Table XOMA Corporate Summary
  • Y-mAbs Therapeutics
    • Table Y-mAbs Therapeutics Corporate Summary
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Ablynx
  • Agensys
  • Alder Biopharmaceuticals
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aptevo Therapeutics
  • AstraZeneca/MedImmune
  • Bayer
  • BioInvent International
  • Biocon Ltd
  • Biogen Inc.
  • Biotest AG
  • Boehringer Ingelheim GmbH
  • CBT Pharmaceuticals
  • Celgene
  • Celldex Therapeutics
  • Celltrion, Inc.
  • Coherus BioSciences, Inc
  • CytoDyn
  • Eisai
  • Eleven Biotherapeutics
  • Eli Lilly & Co.
  • FibroGen Inc.
  • Five Prime Therapeutics
  • Fujifilm Kyowa Kirin Biologics
  • Genmab A/S
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Humanigen, Inc. (previously KaloBios Pharmaceuticals)
  • Immune Pharmaceuticals
  • ImmunoGen Inc.
  • Immunomedics Inc.
  • Innate Pharma
  • InterveXion Therapeutics
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co, Ltd
  • MacroGenics
  • Mapp Biopharmaceutical
  • Merck & Company
  • Merrimack Pharmaceuticals
  • Momenta Pharmaceuticals Inc.
  • MorphoSys
  • Morphotek
  • Mylan N.V.
  • Nascent Biotech
  • Neurimmune
  • Nordic Nanovector
  • Novartis/Sandoz
  • Novimmune SA
  • OncoMed Pharmaceuticals
  • OncoQuest
  • Oncternal Therapeutics
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis Co Ltd
  • Sanofi
  • Seattle Genetics
  • Shire PLC
  • Sorrento Therapeutics
  • TESARO
  • TEVA Pharmaceutical Industries Ltd
  • TG Therapeutics
  • TaiMed Biologics
  • Takeda Oncology
  • ThromboGenics
  • UCB S.A.
  • Unum Therapeutics
  • Vitaeris
  • XBiotech
  • XOMA
  • Xencor
  • Y-mAbs Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll